Mirador Capital Partners LP Acquires New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Mirador Capital Partners LP bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 2,980 shares of the company’s stock, valued at approximately $203,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. ARK Investment Management LLC lifted its holdings in shares of CRISPR Therapeutics by 19.2% during the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after acquiring an additional 1,372,986 shares during the last quarter. Norges Bank bought a new stake in CRISPR Therapeutics during the fourth quarter worth about $38,661,000. Vestmark Advisory Solutions Inc. purchased a new position in shares of CRISPR Therapeutics in the 4th quarter worth about $10,848,000. PBCay One RSC Ltd bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at about $10,329,000. Finally, Trexquant Investment LP purchased a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $8,287,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In related news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total value of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 19,582 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The disclosure for this sale can be found here. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Trading Down 0.1 %

Shares of CRSP opened at $53.95 on Tuesday. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of -19.83 and a beta of 1.70. The firm’s 50-day moving average price is $56.69 and its 200-day moving average price is $64.47.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $25.53 million. The business’s revenue for the quarter was down 99.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.67) EPS. On average, research analysts forecast that CRISPR Therapeutics AG will post -5.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on CRSP. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, May 9th. Piper Sandler reiterated an “overweight” rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a report on Monday, June 17th. JMP Securities restated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $88.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, June 27th. Finally, Robert W. Baird increased their price objective on CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research note on Thursday, May 9th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $75.71.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.